Clinical Trials Directory

Trials / Completed

CompletedNCT01162278

Stereotactic Body Radiation Therapy (SBRT) for Patients With Hepatic Metastases

Dose Escalating Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) for Patients With Hepatic Metastases

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
University of Texas Southwestern Medical Center · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Not accepted

Summary

Patients that have had staging studies identifying them as AJCC stage IV with up to five liver metastases will be considered for the study. About 60 patients will take part in this study at UT southwestern, Parkland Health \& Hospital System, and Methodist Richardson Cancer Center. There are four dose cohorts for this study and each cohort will enroll a minimum of 7 to a maximum of 15 patients depending on tolerance of therapy. The treatment period will last for approximately 1 day and the follow-up portion of the study will last 5 years.

Detailed description

If the patient has met all the eligibility criteria, they will be registered to the study After successful registration to the study and treatment planning session, patients will receive a single fraction of radiation. The total dose a particular patient receives will depend on the dose cohort they are enrolled into. Each treatment will last about one hour and will be given in a particular position to help guide the beams of radiation toward the cancer area. Although it is not mandatory, it is recommended that patients receive corticosteroid premedication (e.g. Decadron 4-10 m.g. p.o. in a single dose or equivalent) 15-60 minutes prior to each treatment for the intended purpose of modulating immediate acute inflammatory effects and providing anti-emetic support.

Conditions

Interventions

TypeNameDescription
RADIATIONSBRTSingle fraction SBRT

Timeline

Start date
2010-07-01
Primary completion
2015-11-25
Completion
2017-11-25
First posted
2010-07-14
Last updated
2020-08-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01162278. Inclusion in this directory is not an endorsement.